Avadel Pharmaceuticals price target raised to $24 from $22 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Avadel Pharmaceuticals (AVDL) to $24 from $22 and keeps a Buy rating on the shares. The company reported a “beat and raise” Q2, the analyst tells investors in a research note.